⚠ Scores are AI-generated estimates for informational purposes only — not investment advice. Data may be inaccurate or outdated. Do not make financial decisions based on this site. Full legal disclaimer →
⚠ Scores are AI-generated estimates for informational purposes only — not investment advice. Data may be inaccurate or outdated. Do not make financial decisions based on this site. Full legal disclaimer →
AI Exposure Analysis
Healthcare · Large Cap · Disruption threat: MEDIUM
Bristol Myers Squibb leverages AI primarily in drug discovery, clinical trial optimization, and biomarker identification, with growing investment in computational biology and data science platforms. AI remains an enabling tool rather than a direct revenue driver, with the company continuing to integrate AI across its R&D pipeline to accelerate development timelines.
Bristol Myers Squibb is a large-cap biopharmaceutical company focused on oncology, immunology, and cardiovascular therapies. With an overall AI score of 47/100, the company occupies a mid-tier position in AI adoption, using artificial intelligence as a pipeline accelerator rather than a commercial differentiator. AI functions as an enabling infrastructure layer, not yet a revenue-generating asset. The score reflects meaningful divergence across dimensions. R&D AI Investment leads at 65/100, consistent with BMS's documented commitments to computational biology, molecular screening, and AI-assisted clinical trial design and patient stratification. Internal AI Use at 55/100 suggests reasonable operational deployment in supply chain and efficiency workflows. However, Revenue from AI scores just 5/100, confirming that AI has not yet translated into quantifiable top-line contribution, while Product AI Integration at 35/100 indicates limited embedding of AI capabilities within marketed therapies. The medium disruption threat reflects a balanced exposure profile. BMS faces competitive pressure from peers accelerating AI-driven drug discovery timelines, but its established pipeline depth and proprietary datasets provide partial insulation against displacement. The primary opportunity lies in converting R&D AI investment into faster regulatory submissions and reduced trial costs. Failure to do so risks ceding pipeline velocity to more AI-native biotech competitors.
Full interactive analysis at RankVis.io